Drug intelligence / Profile preview

CBUD-1001

Development stage: Preclinical
Lead developer: Chungbuk National University
Modality: Small Molecules

Overview

CBUD-1001 is a novel small molecule histone deacetylase (HDAC) inhibitor being investigated for its ability to sensitize colorectal cancer (CRC) cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. The drug works by inducing hyper-acetylation of histones, which leads to the up-regulation of death receptor 5 (DR5) through the MAPK/CHOP signaling axis. This mechanism facilitates mitochondria-mediated apoptotic pathways, helping to overcome TRAIL resistance in CRC cells. It is primarily developed in an academic research setting at Chungbuk National University.

Targets

HDAC1 (Histone Deacetylase 1)

Beyond the preview

Go deeper on CBUD-1001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBUD-1001.

Explore the full profile